Clinical trials: Steroid Refractory
Graft vs. Host Disease
Brentuximab Vedotin for Steroid Refractory GvHD
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational drug. Phase I studies also try to define the appropriate dose of the investigational drug to use for further studies.
- Trial name
- NCT01596218
- Testing
- Brentuximab Vedotin
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Massachusetts General Hospital
Graft-Versus-Host Disease
Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease
This study will evaluate the response rate to treatment with pentostatin in steroid-refractory acute graft versus host disease.
- Trial name
- NCT00201786
- Testing
- Pentostatin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Inflammatory Diseases
Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants
The primary objective of this study is to evaluate the pharmacokinetics (PK) of efavaleukin alfa after single subcutaneous (SC) administration in healthy Chinese, Japanese, and Caucasian participants.
- Trial name
- NCT04987333
- Testing
- Efavaleukin alfa
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amgen
Acute Graft Versus Host Disease in Intestine
FMT for Pediatric SR-aGVHD
This is a pilot, prospective, non-profit, multicenter, uncontrolled, open-label study to evaluate the safety and feasibility of FMT in patients aged between 3 months and 25 years suffering from acute intestinal GVHD resistant to…
- Trial name
- NCT07602751
- Testing
- Fecal Microbial Transplantation
- Where
- 3 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Chronic Graft Versus Host Disease
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
This pilot clinical trial studies how well vismodegib works in treating patients with chronic graft-versus-host disease that did not respond to previous steroid treatment.
- Trial name
- NCT02337517
- Testing
- Laboratory Biomarker Analysis, Vismodegib
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease
Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)
The immune system has offensive and defensive capacities. In bone marrow transplantation, offensive cells in the donor grafts may attack host's organs, leading to a complication known as Graft versus Host Disease (GVDH).
- Conditions
- Chronic Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease, Steroid Refractory Graft-Versus-Host Disease
- Trial name
- NCT01903473
- Testing
- Rapamycin, T regulatory cells
- Where
- 2 sites in Belgium
- Volunteers
- 19 people
- Sponsor
- University of Liege
Graft Versus Host Disease
Identification of Novel Targetable Kinases in SR-a GvHD
In this study, the investigators aim to identify novel targetable kinases in SR-a GvHD patient samples and investigate their role in different immune cell subtypes.
- Trial name
- NCT04342442
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Freiburg
Graft vs Host Disease
Ruxolitinib In GvHD
The preliminary data demonstrate potent activity of Ruxolitinib in steroid-refractory aGvHD. In this phase 2 trial the efficacy of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute GvHD in…
- Trial name
- RIG (NCT02396628)
- Testing
- Experimental intervention, Standard treatment
- Where
- 11 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Prof. Dr. Nikolas von Bubnoff
Change From Baseline House-Brackmann
Ultrasound-Guided Stellate Ganglion Block With Botulinum
the local stellate ganglion block with bupivacaine and corticosteroid treatment for acute peripheral facial nerve palsy in patients can induce hyperglycemia, and an alternative local therapy may be necessary and some time may ve…
- Trial name
- NCT05099835
- Testing
- Botox, triamcinolonacetonide
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Ulcerative Colitis
Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study
The purpose of this study is to compare the efficacy, safety, pharmacokinetics, and immunogenicity in subjects retreated with visilizumab or placebo after a response in a prior visilizumab study.
- Trial name
- NCT00279435
- Testing
- visilizumab
- Where
- 39 sites in United States, Australia and 13 more
- Volunteers
- 25 people
- Sponsor
- Facet Biotech
Steroid Refractory GVHD
Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD
A Phase 3, Multicenter, open label, study to Evaluate the EFficacy and SaFEty of Leukotac® (inolimomab) in pediatric patients with steroid resistant acute Graft versus Host Disease (SR-aGvHD)
- Trial name
- EiFFEL (NCT04289103)
- Testing
- Inolimomab (Leukotac)
- Volunteers
- 65 people
- Sponsor
- ElsaLys Biotech
Steroid-refractory Gastrointestinal Acute Graft Versus Host Disease
Efficacy and Safety of FMT Capsule Treating Steroid-refractory GI-aGvHD
Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD) is a complication of allogeneic stem cell transplant which is usually treated with steroids.
- Trial name
- NCT04622475
- Testing
- Fecal Microbiota Transplant (FMT) Capsule
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Steroid Refractory Graft Versus Host Disease
CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)
The purpose of this study is to determine the efficacy and safety of CK0802 Tregs for treatment of refractory GVHD (graft-versus-host disease)
- Trial name
- NCT07576699
- Testing
- CK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched)
- Volunteers
- 12 people
- Sponsor
- Cellenkos, Inc.
Chronic Graft Versus Host Disease cGVHD
Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease
Phase 1b: To evaluate the safety and tolerability of multiple ascending doses of efavaleukin alfa in subjects with steroid refractory chronic graft versus host disease (cGVHD).
- Trial name
- NCT03422627
- Testing
- Efavaleukin Alfa
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 32 people
- Sponsor
- Amgen
Graft Versus Host Disease
Bortezomib in Patients With Chronic Graft Versus Host Disease
This study will investigate whether bortezomib can control the immune system and can be used to treat GVHD. Bortezomib has been used with not too many serious side effects in patients with multiple myeloma who will undergo…
- Trial name
- NCT01672229
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mehrdad Abedi, MD
Intravenous Steroid-Refractory Ulcerative Colitis
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
To compare the efficacy of visilizumab at 5 mcg/kg/day administered intravenously (IV) on Days 1 and 2 to placebo in subjects with IVSR-UC.
- Trial name
- NCT00502294
- Testing
- Visilizumab (HuM291; Nuvion®)
- Volunteers
- 150 people
- Sponsor
- Facet Biotech
Uveitis, Posterior, Uveitis, Anterior
Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study
The objective of this study is to explore the efficacy of ixekizumab in treating patients with a diagnosis of non-infectious intermediate, posterior, panuveitis, or chronic steroid-dependent anterior uveitis who had failed…
- Conditions
- Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
- Trial name
- NCT06085079
- Testing
- Ixekizumab Prefilled Syringe
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye Research and Surgery Institution
Steroid-Refractory Chronic GVHD
Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
Chronic GVHD is the most common late complication following allogeneic stem cell transplantation. It has features resembling autoimmune disorders such as scleroderma, primary biliary cirrhosis, bronchiolitis obliterans, chronic…
- Trial name
- NCT00472225
- Testing
- Rituximab
- Where
- 9 sites in South Korea
- Volunteers
- 42 people
- Sponsor
- The Korean Society of Hematopoietic Stem Cell Transplantation
Asthma
Immune Interactions in Severe Asthma
This research study is being done to learn more about severe asthma by comparing people with severe asthma to those with milder forms of asthma and people without asthma, at baseline and over time.
- Trial name
- NCT02566668
- Testing
- 1 year Observational Follow-up
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Graft Versus Host Disease
Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids
RATIONALE: Efalizumab may be an effective treatment for graft-versus-host disease of the skin caused by a donor stem cell transplant.
- Trial name
- NRR (NCT00489216)
- Testing
- efalizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center